GEN Exclusives

More »

GEN News Highlights

More »
Jul 28, 2010

HemaQuest Raises $4M to Progress Mid-Stage Development

  • HemaQuest Pharmaceuticals closed an additional $4 million financing to its Series B round. The total Series B investment is now $16 million.

    The money is intended to help advance HemaQuest's two lead products, HQK-1001 and HQK-1004, through Phase IIb trials. HQK-1001 is an orally administered small molecule therapeutic being developed to treat sickle cell disease and beta thalassemia. HemaQuest has been granted orphan drug designation for the compound in both diseases.

    The company obtained the exclusive, worldwide license for this compound from Boston University. HQK-1001 works by inducing fetal globin and stimulating red blood cell production, which addresses the underlying pathological mechanisms in sickle cell disease and beta thalassemia.

    HQK-1004 is designed to treat malignancies associated with Epstein-Barr virus. It acts by inducing the expression of a gene for a viral enzyme, thymidine kinase (TK). This enzyme is the target of several common antiviral drugs, but the gene is silenced in a number of viral-related diseases making them resistant to standard antiviral therapeutics, HemaQuest explains. Inducing the expression of the silenced gene enables the use of these antiviral drugs, such as ganciclovir, to destroy virally infected cells.


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Stopping Research Fraud

What is the best approach to curbing scientific misconduct and outright fraud?